Ninety years in, the Natural Products Association is not slowing down. Over 180 members descended on Capitol Hill last week, per NutraIngredients-USA, pressing legislators on four issues that will shape how Americans buy and use dietary supplements for years to come.
TLDR
- 180-plus NPA members met legislators on Capitol Hill last week.
- Mandatory Product Listing bill is the industry’s top threat to fight.
- HSA and FSA expansion could unlock new supplement purchase channels.
- Drug preclusion clause modernization is central to ingredient innovation.
- State-level regulatory patchwork is forcing a federal clarity push.
Dietary Supplement Regulatory Access: Four Fights on the Table
The NPA’s 2026 fly-in agenda covered four distinct legislative priorities. Each one carries direct consequences for manufacturers, retailers, and ingredient suppliers.
First: opposing the Mandatory Product Listing bill. Critics argue it would create a de facto pre-market approval regime without congressional authorization. The NPA framed it as a threat to consumer access and industry competitiveness.
Second: modernizing the drug preclusion clause. Under current FDA rules, an ingredient studied as a drug can be blocked from the supplement market. NPA members want that barrier updated to reflect modern research realities.
HSA and FSA Expansion Could Reshape the Supplement Market
The third priority is arguably the most commercially significant. Expanding Health Savings Account and Flexible Spending Account eligibility to cover dietary supplements would open a tax-advantaged purchase channel. That shift could meaningfully increase consumer spending power.
Fourth: federal regulatory uniformity. Mountain states have moved independently on supplement rules, creating a fragmented compliance landscape. The Dietary Supplement Regulatory Uniformity Act, introduced by Congressman Nick Langworthy (R-NY), aims to reassert FDA primacy. Operators managing multi-state distribution know exactly why this matters.
Additionally, the NDA regulatory backdrop is active. The FDA recently reinstated NMN’s new dietary ingredient status, a signal that agency posture on novel ingredients remains fluid. NPA’s timing is deliberate.
In short, the supplement industry is not waiting for regulators to set the terms. It is lobbying to write them. For operators tracking clean-label and transparency trends, federal clarity on supplement rules is a prerequisite for responsible innovation.
Source: NutraIngredients-USA. https://www.nutraingredients.com/Article/2026/05/14/npa-fly-in-day-2026/